Clustering data with hclust algorithm for PGD2 and other lipid mediator changes in mouse adipose associated with administration of an oral inhibitor of H-PGDS (HQL-79) (part II) (Study ST000594)

Reversed phase NEGATIVE ION MODE (Analysis AN000910)
MetaboliteStructureF1F2
15-Keto PGE2ME1709491.480.52
9_12_13-TriHOMEME1709581.270.73
PGE3ME1710031.130.89
PGE2ME1709481.130.87
12(13)-Ep-9-KODEME1709901.120.88
12(13)-EpODEME1709921.120.88
15(16)-EpODEME1709911.090.91
11(12)-EpETrEME1709951.110.89
TXB2ME1709461.100.90
9(10)-EpODEME1709931.100.90
14(15)-EpETrEME1709941.100.90
8(9)-EpETrEME1709961.100.90
12_13-DiHOMEME1709601.230.77
9-KODEME1709991.210.79
13-KODEME1709981.180.82
9(10)-EpOMEME1709891.180.82
9_10-EpOME1709871.190.81
9_10-DiHOMEME1709611.190.81
9_10-e-DiHOME1709591.190.81
PGF2aME1709521.170.83
12(13)-EpOMEME1709881.160.84
PGE1ME1709471.160.84
8_15-DiHETEME1709570.731.27
12-HETEME1709760.751.25
15-HETEME1709750.771.23
19_20-DiHDoPAME1709690.611.39
14-HDoHEME1709850.671.33
15_16-DiHODEME1709620.681.32
5_6-DiHETrEME1709670.691.31
15-deoxy PGJ2ME1709511.020.98
20-HETEME1709741.020.99
9-HOTEME1709731.030.97
Lipoxin A4ME1709541.040.96
10-NitrooleateME1710020.991.01
17_18-DiHETEME1709680.981.02
9_10-DiHODEME1709630.981.02
PGD2ME1709500.971.03
6-keto PGF1aME1709450.961.04
9-HODEME1709710.961.04
11-HETEME1709530.861.14
5-HETEME1709790.861.14
8-HETEME1709780.851.15
9-HETEME1709770.851.15
11_12-DiHETrEME1709650.831.17
8_9-DiHETrEME1709660.831.17
14_15-DiHETrEME1709640.811.19
15-HEPEME1709800.821.18
17-HDoHEME1709840.881.12
5-HEPEME1709830.871.13
15-KETEME1710000.891.11
12-HEPEME1709810.891.11
13-HOTEME1709720.891.11
13-HODEME1709700.901.10
19(20)-EpDPEME1709970.901.10
5-KETEME1710010.931.07
9-HEPEME1709820.941.06
5_15-DiHETEME1709560.921.08
4-HDoHEME1709860.911.09
6-trans-LTB4ME1709550.911.09

Factors:

F1Treatment:HQL-79
F2Treatment:Vehicle
Data matrix
  logo